![](https://cdn.koreabiomed.com/news/thumbnail/202407/24643_25597_2436_v150.jpg)
New blood cancer drugs reach Korea but insurance delays hinder survival rates: expert
Game-changing new drugs have been developed and introduced to Korea for treating blood cancers, including multiple myeloma. Still, an expert pointed out the nation’s gap in survival rates with advanced countries has not narrowed much. Noting that the …